Hierarchical cluster analysis of cytokine profiles reveals a cutaneous vasculitis-associated subgroup in dermatomyositis

go back to reference Sontheimer RD (2010) Clinically amyopathic dermatomyositis: what can we now tell our patients. Arch Dermatol 146(1):76–80. https://doi.org/10.1001/archdermatol.2009.323CrossRefPubMed Sontheimer RD (2010) Clinically amyopathic dermatomyositis: what can we now tell our patients. Arch Dermatol 146(1):76–80. https://​doi.​org/​10.​1001/​archdermatol.​2009.​323CrossRefPubMed

go back to reference Motegi SI, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M, Ikeuchi H, Sakairi T, Hara K, Yamaguchi K, Maeno T, Hiromura K, Ishikawa O (2019) Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol 29(5):511–517. https://doi.org/10.1684/ejd.2019.3634CrossRefPubMed Motegi SI, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M, Ikeuchi H, Sakairi T, Hara K, Yamaguchi K, Maeno T, Hiromura K, Ishikawa O (2019) Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol 29(5):511–517. https://​doi.​org/​10.​1684/​ejd.​2019.​3634CrossRefPubMed

go back to reference Yamasaki Y, Satoh M, Mizushima M, Okazaki T, Nagafuchi H, Ooka S, Shibata T, Nakano H, Ogawa H, Azuma K, Maeda A, Tonooka K, Ito H, Takakuwa Y, Inoue M, Mitomi H, Kiyokawa T, Tsuchida K, Matsushita H, Mikage H, Murakami Y, Chan JY, Ozaki S, Yamada H (2016) Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52. Mod Rheumatol 26(3):403–409. https://doi.org/10.3109/14397595.2015.1091155CrossRefPubMed Yamasaki Y, Satoh M, Mizushima M, Okazaki T, Nagafuchi H, Ooka S, Shibata T, Nakano H, Ogawa H, Azuma K, Maeda A, Tonooka K, Ito H, Takakuwa Y, Inoue M, Mitomi H, Kiyokawa T, Tsuchida K, Matsushita H, Mikage H, Murakami Y, Chan JY, Ozaki S, Yamada H (2016) Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52. Mod Rheumatol 26(3):403–409. https://​doi.​org/​10.​3109/​14397595.​2015.​1091155CrossRefPubMed

go back to reference Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L (2015) Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol 72(3):449–455. https://doi.org/10.1016/j.jaad.2014.12.009CrossRefPubMedPubMedCentral Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L (2015) Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol 72(3):449–455. https://​doi.​org/​10.​1016/​j.​jaad.​2014.​12.​009CrossRefPubMedPubMedCentral

go back to reference Muro Y, Sugiura K, Akiyama M (2016) Cutaneous manifestations in dermatomyositis: key clinical and serological features-a comprehensive review. Clin Rev Allergy Immunol 51(3):293–302. https://doi.org/10.1007/s12016-015-8496-5CrossRefPubMed Muro Y, Sugiura K, Akiyama M (2016) Cutaneous manifestations in dermatomyositis: key clinical and serological features-a comprehensive review. Clin Rev Allergy Immunol 51(3):293–302. https://​doi.​org/​10.​1007/​s12016-015-8496-5CrossRefPubMed

go back to reference Aussy A, Fréret M, Gallay L, Bessis D, Vincent T, Jullien D, Drouot L, Jouen F, Joly P, Marie I, Meyer A, Sibilia J, Bader-Meunier B, Hachulla E, Hamidou M, Huë S, Charuel JL, Fabien N, Viailly PJ, Allenbach Y, Benveniste O, Cordel N, Boyer O (2019) The IgG2 isotype of anti-transcription intermediary factor 1γ autoantibodies is a biomarker of cancer and mortality in adult dermatomyositis. Arthritis Rheumatol 71(8):1360–1370. https://doi.org/10.1002/art.40895CrossRefPubMed Aussy A, Fréret M, Gallay L, Bessis D, Vincent T, Jullien D, Drouot L, Jouen F, Joly P, Marie I, Meyer A, Sibilia J, Bader-Meunier B, Hachulla E, Hamidou M, Huë S, Charuel JL, Fabien N, Viailly PJ, Allenbach Y, Benveniste O, Cordel N, Boyer O (2019) The IgG2 isotype of anti-transcription intermediary factor 1γ autoantibodies is a biomarker of cancer and mortality in adult dermatomyositis. Arthritis Rheumatol 71(8):1360–1370. https://​doi.​org/​10.​1002/​art.​40895CrossRefPubMed

go back to reference Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, Takagi K, Ichida H, Katsumata Y, Ota Y, Kawasumi H, Yamanaka H (2014) Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford) 53(12):2196–2203. https://doi.org/10.1093/rheumatology/keu258CrossRef Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, Takagi K, Ichida H, Katsumata Y, Ota Y, Kawasumi H, Yamanaka H (2014) Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford) 53(12):2196–2203. https://​doi.​org/​10.​1093/​rheumatology/​keu258CrossRef

go back to reference To F, Parker MJS, Ventín-Rodríguez C, Lilleker JB, Chinoy H (2019) Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria. Rheumatology (Oxford) 58(12):2331–2333. https://doi.org/10.1093/rheumatology/kez253CrossRef To F, Parker MJS, Ventín-Rodríguez C, Lilleker JB, Chinoy H (2019) Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria. Rheumatology (Oxford) 58(12):2331–2333. https://​doi.​org/​10.​1093/​rheumatology/​kez253CrossRef

go back to reference Asakawa K, Yoshizawa K, Aoki A, Kimura Y, Tanaka T, Ohashi K, Hayashi M, Kikuchi T, Sato S, Takada T (2020) Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies. Clin Rheumatol 39:2171–2178. https://doi.org/10.1007/s10067-020-04984-xCrossRefPubMed Asakawa K, Yoshizawa K, Aoki A, Kimura Y, Tanaka T, Ohashi K, Hayashi M, Kikuchi T, Sato S, Takada T (2020) Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies. Clin Rheumatol 39:2171–2178. https://​doi.​org/​10.​1007/​s10067-020-04984-xCrossRefPubMed

go back to reference Matsuda S, Kotani T, Ishida T, Fukui K, Fujiki Y, Suzuka T, Nagai K, Hata K, Shoda T, Isoda K, Ito Y, Makino S, Takeuchi T, Arawaka S (2020) Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis-interstitial lung disease. Rheumatology (Oxford) 59(2):310–318. https://doi.org/10.1093/rheumatology/kez301CrossRef Matsuda S, Kotani T, Ishida T, Fukui K, Fujiki Y, Suzuka T, Nagai K, Hata K, Shoda T, Isoda K, Ito Y, Makino S, Takeuchi T, Arawaka S (2020) Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis-interstitial lung disease. Rheumatology (Oxford) 59(2):310–318. https://​doi.​org/​10.​1093/​rheumatology/​kez301CrossRef

go back to reference Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, Meyer A, Guillaud C, Limal N, Gagnadoux F, Hervier B, Borie R, Deligny C, Terrier B, Berezne A, Audia S, Champtiaux N, Devilliers H, Voermans N, Diot E, Servettaz A, Marhadour T, Castelain V, Humbert S, Blanchard-Delaunay C, Tieulie N, Charles P, Gerin M, Mekinian A, Priou P, Meurice JC, Tazi A, Cottin V, Miyara M, Grange B, Israël-Biet D, Phin-Huynh S, Bron C, De Saint ML, Fabien N, Mariampillai K, Nunes H, Benveniste O (2020) Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. Neurology. https://doi.org/10.1212/WNL.0000000000009727 Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, Meyer A, Guillaud C, Limal N, Gagnadoux F, Hervier B, Borie R, Deligny C, Terrier B, Berezne A, Audia S, Champtiaux N, Devilliers H, Voermans N, Diot E, Servettaz A, Marhadour T, Castelain V, Humbert S, Blanchard-Delaunay C, Tieulie N, Charles P, Gerin M, Mekinian A, Priou P, Meurice JC, Tazi A, Cottin V, Miyara M, Grange B, Israël-Biet D, Phin-Huynh S, Bron C, De Saint ML, Fabien N, Mariampillai K, Nunes H, Benveniste O (2020) Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. Neurology. https://​doi.​org/​10.​1212/​WNL.​0000000000009727​

go back to reference Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347. https://doi.org/10.1056/nejm197502132920706CrossRefPubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347. https://​doi.​org/​10.​1056/​nejm197502132920​706CrossRefPubMed

go back to reference Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness. J Am Acad Dermatol 46(4):626–636. https://doi.org/10.1067/mjd.2002.120621CrossRefPubMed Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness. J Am Acad Dermatol 46(4):626–636. https://​doi.​org/​10.​1067/​mjd.​2002.​120621CrossRefPubMed

go back to reference Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE Jr, Bradford WZ, Schwartz DA, Richard Webb W, Idiopathic Pulmonary Fibrosis Study G (2005) High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 172(4):488–493. https://doi.org/10.1164/rccm.200412-1756OCCrossRefPubMed Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE Jr, Bradford WZ, Schwartz DA, Richard Webb W, Idiopathic Pulmonary Fibrosis Study G (2005) High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 172(4):488–493. https://​doi.​org/​10.​1164/​rccm.​200412-1756OCCrossRefPubMed

go back to reference Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res 63(Suppl 11 (0 11)):S118–S157. https://doi.org/10.1002/acr.20532CrossRef Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res 63(Suppl 11 (0 11)):S118–S157. https://​doi.​org/​10.​1002/​acr.​20532CrossRef

go back to reference Chen M, Quan C, Diao L, Xue F, Xue K, Wang B, Li X, Zhu X, Zheng J, Cao H (2018) Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis. Br J Dermatol 179(6):1334–1341. https://doi.org/10.1111/bjd.17079CrossRefPubMed Chen M, Quan C, Diao L, Xue F, Xue K, Wang B, Li X, Zhu X, Zheng J, Cao H (2018) Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis. Br J Dermatol 179(6):1334–1341. https://​doi.​org/​10.​1111/​bjd.​17079CrossRefPubMed

go back to reference Szodoray P, Alex P, Knowlton N, Centola M, Dozmorov I, Csipo I, Nagy AT, Constantin T, Ponyi A, Nakken B, Danko K (2010) Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford) 49(10):1867–1877. https://doi.org/10.1093/rheumatology/keq151CrossRef Szodoray P, Alex P, Knowlton N, Centola M, Dozmorov I, Csipo I, Nagy AT, Constantin T, Ponyi A, Nakken B, Danko K (2010) Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford) 49(10):1867–1877. https://​doi.​org/​10.​1093/​rheumatology/​keq151CrossRef

go back to reference Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, Bardi G, Baggiolini M, Clark-Lewis I (2001) The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 276(5):2986–2991. https://doi.org/10.1074/jbc.M005652200CrossRefPubMed Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, Bardi G, Baggiolini M, Clark-Lewis I (2001) The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 276(5):2986–2991. https://​doi.​org/​10.​1074/​jbc.​M005652200CrossRefPubMed

go back to reference Uruha A, Noguchi S, Sato W, Nishimura H, Mitsuhashi S, Yamamura T, Nishino I (2015) Plasma IP-10 level distinguishes inflammatory myopathy. Neurology 85(3):293–294. https://doi.org/10.1212/wnl.0000000000001767CrossRefPubMed Uruha A, Noguchi S, Sato W, Nishimura H, Mitsuhashi S, Yamamura T, Nishino I (2015) Plasma IP-10 level distinguishes inflammatory myopathy. Neurology 85(3):293–294. https://​doi.​org/​10.​1212/​wnl.​0000000000001767​CrossRefPubMed

go back to reference Limongi F (2015) The CXCR3 chemokines in inflammatory myopathies. Clin Ter 166(1):e56–e61. https://doi.org/10.7417/ct.2015.1810CrossRefPubMed Limongi F (2015) The CXCR3 chemokines in inflammatory myopathies. Clin Ter 166(1):e56–e61. https://​doi.​org/​10.​7417/​ct.​2015.​1810CrossRefPubMed

go back to reference Wenzel J, Schmidt R, Proelss J, Zahn S, Bieber T, Tüting T (2006) Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 31(4):576–582. https://doi.org/10.1111/j.1365-2230.2006.02150.xCrossRefPubMed Wenzel J, Schmidt R, Proelss J, Zahn S, Bieber T, Tüting T (2006) Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 31(4):576–582. https://​doi.​org/​10.​1111/​j.​1365-2230.​2006.​02150.​xCrossRefPubMed

go back to reference Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Watson KD, Lunt M, Symmons DP (2011) The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 50(7):1341–1342. https://doi.org/10.1093/rheumatology/ker146CrossRef Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Watson KD, Lunt M, Symmons DP (2011) The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 50(7):1341–1342. https://​doi.​org/​10.​1093/​rheumatology/​ker146CrossRef

go back to reference Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68(1):25–32. https://doi.org/10.1136/ard.2007.083188CrossRefPubMed Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68(1):25–32. https://​doi.​org/​10.​1136/​ard.​2007.​083188CrossRefPubMed

go back to reference Ji DX, Yamashiro LH, Chen KJ, Mukaida N, Kramnik I, Darwin KH, Vance RE (2019) Type I interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. Nat Microbiol 4(12):2128–2135. https://doi.org/10.1038/s41564-019-0578-3CrossRefPubMedPubMedCentral Ji DX, Yamashiro LH, Chen KJ, Mukaida N, Kramnik I, Darwin KH, Vance RE (2019) Type I interferon-driven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. Nat Microbiol 4(12):2128–2135. https://​doi.​org/​10.​1038/​s41564-019-0578-3CrossRefPubMedPubMedCentral

go back to reference Son K, Tomita Y, Shimizu T, Nishinarita S, Sawada S, Horie T (2000) Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis. Intern Med 39(2):128–135. https://doi.org/10.2169/internalmedicine.39.128CrossRefPubMed Son K, Tomita Y, Shimizu T, Nishinarita S, Sawada S, Horie T (2000) Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis. Intern Med 39(2):128–135. https://​doi.​org/​10.​2169/​internalmedicine​.​39.​128CrossRefPubMed

go back to reference De Bleecker JL, De Paepe B, Vanwalleghem IE, Schröder JM (2002) Differential expression of chemokines in inflammatory myopathies. Neurology 58(12):1779–1785. https://doi.org/10.1212/wnl.58.12.1779CrossRefPubMed De Bleecker JL, De Paepe B, Vanwalleghem IE, Schröder JM (2002) Differential expression of chemokines in inflammatory myopathies. Neurology 58(12):1779–1785. https://​doi.​org/​10.​1212/​wnl.​58.​12.​1779CrossRefPubMed

go back to reference DeWane ME, Waldman R, Lu J (2020) Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol 82(2):267–281. https://doi.org/10.1016/j.jaad.2019.06.1309CrossRefPubMed DeWane ME, Waldman R, Lu J (2020) Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol 82(2):267–281. https://​doi.​org/​10.​1016/​j.​jaad.​2019.​06.​1309CrossRefPubMed

go back to reference Kim H, Gunter-Rahman F, McGrath JA, Lee E, de Jesus AA, Targoff IN, Huang Y, O’Hanlon TP, Tsai WL, Gadina M, Miller FW, Goldbach-Mansky R, Rider LG (2020) Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Res Ther 22(1):69–69. https://doi.org/10.1186/s13075-020-02160-9CrossRefPubMedPubMedCentral Kim H, Gunter-Rahman F, McGrath JA, Lee E, de Jesus AA, Targoff IN, Huang Y, O’Hanlon TP, Tsai WL, Gadina M, Miller FW, Goldbach-Mansky R, Rider LG (2020) Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Res Ther 22(1):69–69. https://​doi.​org/​10.​1186/​s13075-020-02160-9CrossRefPubMedPubMedCentral

go back to reference Dourmishev LA, Dourmishev AL (2009) Dermatomyositis: advances in recognition, understanding and management.Springer,Verlag Berlin Heidelberg Dourmishev LA, Dourmishev AL (2009) Dermatomyositis: advances in recognition, understanding and management.Springer,Verlag Berlin Heidelberg

go back to reference Miller FW, Oddis CV (2012) Vasculitis in the Idiopathic Inflammatory Myopathies. In: Hoffman GS (ed) Inflammatory Diseases of Blood Vessels. Wiley, New York, pp 433-440 Miller FW, Oddis CV (2012) Vasculitis in the Idiopathic Inflammatory Myopathies. In: Hoffman GS (ed) Inflammatory Diseases of Blood Vessels. Wiley, New York, pp 433-440

go back to reference Ono N, Kai K, Maruyama A, Sakai M, Sadanaga Y, Koarada S, Inoue T, Tada Y (2019) The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology (Oxford) 58(5):786–791. https://doi.org/10.1093/rheumatology/key386CrossRef Ono N, Kai K, Maruyama A, Sakai M, Sadanaga Y, Koarada S, Inoue T, Tada Y (2019) The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology (Oxford) 58(5):786–791. https://​doi.​org/​10.​1093/​rheumatology/​key386CrossRef

go back to reference Asdonk T, Steinmetz M, Krogmann A, Ströcker C, Lahrmann C, Motz I, Paul-Krahe K, Flender A, Schmitz T, Barchet W, Hartmann G, Nickenig G, Zimmer S (2016) MDA-5 activation by cytoplasmic double-stranded RNA impairs endothelial function and aggravates atherosclerosis. J Cell Mol Med 20(9):1696–1705. https://doi.org/10.1111/jcmm.12864CrossRefPubMedPubMedCentral Asdonk T, Steinmetz M, Krogmann A, Ströcker C, Lahrmann C, Motz I, Paul-Krahe K, Flender A, Schmitz T, Barchet W, Hartmann G, Nickenig G, Zimmer S (2016) MDA-5 activation by cytoplasmic double-stranded RNA impairs endothelial function and aggravates atherosclerosis. J Cell Mol Med 20(9):1696–1705. https://​doi.​org/​10.​1111/​jcmm.​12864CrossRefPubMedPubMedCentral